secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001564590-22-020389
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD Q1 net loss $49M on flat revenue; completes $150M vitaCare sale
------------------------------------------------------------------------------

- Total net product revenue $19.3M, down slightly from $19.6M Q1 2021.
- Net loss $49.0M ($5.69 per share) vs $39.4M loss year ago; includes $8.4M debt extinguishment loss.
- Cash $30.4M at March 31, down from $65.1M Dec 2021; used $120M vitaCare proceeds to reduce debt.
- ANNOVERA prescriptions up 27% YoY to 8,014; new prescribers up 16% YoY.
- Completed $150M divestiture of vitaCare in five weeks; $16M PIK fee waived.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000156459022020389/0001564590-22-020389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000156459022020389/txmd-8k_20220516.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-020389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer